Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-024-01386-z
Abstract: Inotuzumab ozogamicin is an antibody-drug conjugate approved for treating relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in adults. Pediatric pharmacokinetic data of inotuzumab ozogamicin are lacking. This study is the first to examine the population… read more here.
Keywords: time; inotuzumab ozogamicin; population; relapsed refractory ... See more keywords
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.10512
Abstract: 10512Background: Inotuzumab ozogamicin (InO), a CD22-targeting antibody linked to calicheamicin demonstrated exceptional activity in R/R ALL in adults. InO has been available to pediatric patients ... read more here.
Keywords: relapsed refractory; refractory acute; ozogamicin pediatric; patients relapsed ... See more keywords